ADAP - Adaptimmune Therapeutics

-

$undefined

N/A

(N/A)

Adaptimmune Therapeutics NasdaqCM:ADAP Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Location: 60 Jubilee Avenue, Abingdon, OX14 4RX, United Kingdom | Website: https://www.adaptimmune.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

431.1M

Cash

59.56M

Avg Qtr Burn

-26.96M

Short % of Float

0.41%

Insider Ownership

0.30%

Institutional Own.

43.51%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Lete-cel (NY-ESO) Details
Myxoid/Round cell liposarcoma, Sarcoma

BLA

Submission

Phase 2

Update

TC-510 Details
Cancer, Colorectal cancer , Ovarian cancer, Mesothelioma, Triple-negative breast cancer , Pancreatic cancer

Failed

Discontinued

TC-110 (CD19) Details
Non-Hodgkin lymphoma, Leukemia, Acute lymphoblastic leukemia, Diffuse large B cell lymphoma, Cancer

Failed

Discontinued

Gavo-cel (TC-210) (Mesothelin) + nivolumab Details
Solid tumor/s, Ovarian cancer, Cancer

Failed

Discontinued

ADP-A2AFP Details
Hepatocellular carcinoma, Cancer

Failed

Discontinued

Uzatresgene autoleucel (uza-cel)(ADP-A2M4CD8) (MAGE A4) +/- nivolumab Details
Head and neck cancer, Bladder cancer, Cancer, Solid tumor/s, Urothelial cancer

Failed

Discontinued

afami-cel (afamitresgene autoleucel) (ADP-A2M4) + pembro Details
Head and neck cancer, Homozygous familial hypercholesterolemia, Cancer, Solid tumor/s

Failed

Discontinued